$14.22
+0.06
(+0.42%)▲
Insights on Amylyx Pharmaceuticals, Inc.
Revenue is up for the last 6 quarters, 285.0K → 102.69M (in $), with an average increase of 43.4% per quarter
Netprofit is down for the last 2 quarters, 22.07M → 20.89M (in $), with an average decrease of 5.4% per quarter
In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 137.6%
5.63%
Downside
Day's Volatility :6.06%
Upside
0.46%
16.88%
Downside
52 Weeks Volatility :71.81%
Upside
66.09%
Period | Amylyx Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -31.1% | -1.3% | 0.0% |
6 Months | -43.53% | 1.2% | 0.0% |
1 Year | -63.75% | -5.7% | -6.5% |
3 Years | -21.31% | 18.2% | -3.8% |
Market Capitalization | 853.4M |
Book Value | $6.2 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 0.01 |
PE Ratio | 1264.0 |
Wall Street Target Price | 39.4 |
Profit Margin | 0.62% |
Operating Margin TTM | 18.23% |
Return On Assets TTM | -1.49% |
Return On Equity TTM | 0.65% |
Revenue TTM | 294.2M |
Revenue Per Share TTM | 4.41 |
Quarterly Revenue Growth YOY | 29666.1% |
Gross Profit TTM | -74.2M |
EBITDA | -6.8M |
Diluted Eps TTM | 0.01 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.86 |
EPS Estimate Next Year | 1.35 |
EPS Estimate Current Quarter | 0.44 |
EPS Estimate Next Quarter | 0.54 |
What analysts predicted
Upside of 177.07%
Sell
Neutral
Buy
Amylyx Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Amylyx Pharmaceuticals, Inc. | -21.09% | -43.53% | -63.75% | -21.31% | -21.31% |
![]() Moderna, Inc. | 12.07% | -38.83% | -56.22% | -44.17% | 329.19% |
![]() Regeneron Pharmaceuticals, Inc. | -0.48% | 10.12% | 6.32% | 61.32% | 112.97% |
![]() Novo Nordisk A/s | -0.53% | 27.78% | 58.23% | 194.69% | 336.14% |
![]() Seagen, Inc. | -0.96% | 8.88% | 73.78% | 20.15% | 232.63% |
![]() Vertex Pharmaceuticals Incorporated | -6.74% | 5.21% | 9.27% | 54.9% | 90.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Amylyx Pharmaceuticals, Inc. | 1264.0 | 1264.0 | NA | 0.86 | 0.01 | -0.01 | 0.0 | 6.2 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Amylyx Pharmaceuticals, Inc. | Buy | $853.4M | -21.31% | 1264.0 | 0.62% |
![]() Moderna, Inc. | Buy | $29.6B | 329.19% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 112.97% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 336.14% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 232.63% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 90.18% | 26.52 | 35.94% |
Vanguard Group Inc
BlackRock Inc
Viking Global Investors LP
Perceptive Advisors LLC
Stonepine Capital Management Llc
Boxer Capital LLC
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
Organization | Amylyx Pharmaceuticals, Inc. |
Employees | 374 |
CEO | Mr. Joshua B. Cohen |
Industry | Services |
Tilly's Inc
$14.22
+0.42%
Bristow Group Inc
$14.22
+0.42%
Dennys
$14.22
+0.42%
Theseus Pharmaceuticals, Inc.
$14.22
+0.42%
H&e Equipment Services Inc
$14.22
+0.42%
Rumbleon Inc
$14.22
+0.42%
Barrett Business Services Inc
$14.22
+0.42%
Jianzhi Education Technology Group Company Ltd.
$14.22
+0.42%
America's Car-mart Inc
$14.22
+0.42%